Effect of ciprofloxacin on levels of lipopolysaccharide and cytokines in experimentally induced gram-negative bacterial pneumonia in mice.
This study was performed to examine the ability of ciprofloxacin (CPFX) to suppress the inflammation associated with lipopolysaccharide (LPS) and an inflammatory cytokine in gram-negative bacterial pneumonia. For this purpose we measured viable cell counts in bronchoalveolar lavage fluid (BALF), LPS concentrations in BALF, and BALF levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) in mice exposed to Klebsiella pneumoniae. We used three groups of mice: controls, treated with physiological saline; mice treated with CPFX; and mice treated with ceftadizime (CAZ). The viable cell count in BALF was low in both the CAZ and CPFX groups. LPS values in BALF were significantly lower in the CPFX group than in the CAZ group at 48 and 72 h after K. pneumoniae exposure (48 h, P < 0.001; 72 h, P < 0.05). The BALF TNF-alpha level was significantly higher in the CAZ group at 24, 48, and 72 h compared to levels in the control and CPFX groups (P < 0.05). In conclusion, these results suggest that CPFX inhibited increases of LPS and TNF-alpha in gram-negative bacterial pneumonia, thereby suppressing the lung inflammation that accompanies pneumonia.
Kawai
Shin
S
The First Department of Internal Medicine, Kyorin University, School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. shinkwi@kyorin-u.ac.jp
Nakagawa
Tomoyuki
T
Sakayori
Susumu
S
Kobayashi
Osamu
O
Kamiya
Shigeru
S
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology / Q000382:microbiology; D002939:Ciprofloxacin / Q000494:pharmacology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000276:immunology; D007711:Klebsiella pneumoniae; D008070:Lipopolysaccharides / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008813:Mice, Inbred ICR; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000382:microbiology
D000890:Anti-Infective Agents; D016207:Cytokines; D008070:Lipopolysaccharides; D002939:Ciprofloxacin